HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market News: Baze Patents ‘Recommendation Engine,' Built Brands Revamps, Expands Capacity

Executive Summary

Leafreport found 54% of 22 beverages contained less CBD than labeled; Built Brands rebrands protein, energy lineup with bigger facility to boost production; Baze Labs’ personalized nutrition “recommendation engine” patented; TruTrace blockchain platform for sanitizer; and Coffeeberry extract GRAS cleared by FDA.

You may also be interested in...



Digital Citizens Study Finds Many CBD Products Are Placebos And Most Are Inaccurately Labeled

Digital Citizens Alliance found an average 30% discrepancy between labeled and actual CBD amounts in nearly 60 products. The group says more than half the products tested contained CBD levels 20% higher or lower than labeled, which is particularly problematic since nearly half US consumers use the products as alternatives to Rx drugs.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel